Compass Financial Management
ATNM icon

Compass Financial Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Compass Financial Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$436K Sell
389,230
-211,000
-35% -$214K 0.05% 313
2026
Q2 		$588K Buy
+600,230
New +$693K 0.07% 251

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Gagnon Securities
Gagnon Securities New York $577M AUM 61.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
AIS
AM Investment Strategies Chattanooga, Tennessee $535M AUM 22.04% 1-Year Est. Return
Gen-Wealth Partners
Gen-Wealth Partners Zeeland, Michigan $356M AUM 21.02% 1-Year Est. Return

Compass Financial Management's ATNM Position: Q3 2026 in Review

Compass Financial Management reduced its Actinium Pharmaceuticals (ATNM) stake by 35% in Q3 2026, selling an estimated $214K and leaving 389,230 shares worth $436K. The position accounts for 0.05% of the portfolio, ranked #313.

Compass Financial Management first reported a position in ATNM in Q2 2026 and has held it in 2 quarters since. The position peaked at $588K in Q2 2026. 38 funds tracked by Wall St. Rank hold ATNM as of Q3 2026.

  • Compass Financial Management held 389,230 shares of Actinium Pharmaceuticals worth $436K as of Q3 2026.
  • Compass Financial Management sold 211,000 Actinium Pharmaceuticals shares in Q3 2026, an estimated $214K.
  • Actinium Pharmaceuticals made up 0.05% of Compass Financial Management's portfolio in Q3 2026, its #313 holding.
  • Compass Financial Management first reported a position in Actinium Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Compass Financial Management's Actinium Pharmaceuticals position peaked at $588K in Q2 2026.
  • 38 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2026.

Based on Compass Financial Management's 13F filing for Q3 2026, filed 30 Oct 2026.